Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023

SELL
$0.64 - $1.99 $3,200 - $9,950
-5,000 Reduced 3.05%
159,000 $176,000
Q3 2022

Nov 14, 2022

BUY
$2.73 - $4.92 $447,720 - $806,880
164,000 New
164,000 $384,000
Q3 2020

Nov 16, 2020

SELL
$4.58 - $10.95 $143,354 - $342,735
-31,300 Closed
0 $0
Q2 2020

Aug 14, 2020

SELL
$4.17 - $7.58 $1.23 Million - $2.23 Million
-294,200 Reduced 90.38%
31,300 $216,000
Q1 2020

May 15, 2020

BUY
$2.91 - $8.7 $289,836 - $866,519
99,600 Added 44.09%
325,500 $1.55 Million
Q4 2019

Feb 14, 2020

BUY
$2.81 - $9.21 $203,163 - $665,883
72,300 Added 47.07%
225,900 $1.97 Million
Q3 2019

Nov 14, 2019

SELL
$3.33 - $4.93 $314,019 - $464,899
-94,300 Reduced 38.04%
153,600 $511,000
Q2 2019

Aug 14, 2019

BUY
$4.3 - $6.73 $89,440 - $139,984
20,800 Added 9.16%
247,900 $1.23 Million
Q1 2019

May 15, 2019

SELL
$3.43 - $6.87 $244,216 - $489,144
-71,200 Reduced 23.87%
227,100 $1.41 Million
Q4 2018

Feb 14, 2019

BUY
$2.69 - $6.71 $255,550 - $637,450
95,000 Added 46.73%
298,300 $1.01 Million
Q3 2018

Nov 13, 2018

BUY
$6.5 - $8.37 $1.32 Million - $1.7 Million
203,300 New
203,300 $1.32 Million

Others Institutions Holding JNCE

About Jounce Therapeutics, Inc.


  • Ticker JNCE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 51,694,200
  • Description
  • Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...
More about JNCE
Track This Portfolio

Track Bridgeway Capital Management, LLC Portfolio

Follow Bridgeway Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bridgeway Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Bridgeway Capital Management, LLC with notifications on news.